Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
Clinical Cancer Research(1)
Clinical and Experimental Immunology(1)
Expert Review of Vaccines(1)
Seminars in Oncology(1)
Origen
scopus(4)
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusCIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
ReviewAbstract: Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in tPalabras claves:cancer vaccine, clinical trials, Epidermal growth factor, Epidermal growth factor receptor, lung cancer, Non-small-cell lung cancerAutores:García Verdecia B., Lage Davila A., Neninger Vinageras E., Rodríguez P.C., Tania CrombetFuentes:scopusDifferential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
ArticleAbstract: Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cPalabras claves:immunotherapy, long-term survival, non–small cell lung cancer, survival mixture modelsAutores:Alfonso S., Carmen Elena Viada, Lage Davila A., Luaces P.L.o., Muchene L., Neninger Vinageras E., Rodríguez P.C., Sánchez L., Shkedy Z., Tania CrombetFuentes:scopusThe anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
ArticleAbstract: Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging rPalabras claves:CD6, Clinical trial, Itolizumab, Phase I, Rheumatoid ArthritisAutores:Aira L.E., Ávila Y., Barrese Y., Carmen Elena Viada, Gómez J.A., Hernández I.M., Hernández M.V., Hernández P., López A.M., Martínez J.P., Milera J.M., Molinero C., Montero E., Moreno E., Prada D.M., Reyes Y., Rodríguez P.C., Torres R.Fuentes:scopus